Corvus Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CRVS Key Statistics
Stock Snapshot
As of today, Corvus Pharmaceuticals(CRVS) shares are valued at $6.75. The company's market cap stands at 506.34M, with a P/E ratio of -12.69.
On 2026-01-10, Corvus Pharmaceuticals(CRVS) stock traded between a low of $6.66 and a high of $7.05. Shares are currently priced at $6.75, which is +1.4% above the low and -4.3% below the high.
Corvus Pharmaceuticals(CRVS) shares are trading with a volume of 1.68M, against a daily average of 1.51M.
During the past year, Corvus Pharmaceuticals(CRVS) stock moved between $2.54 at its lowest and $9.60 at its peak.
During the past year, Corvus Pharmaceuticals(CRVS) stock moved between $2.54 at its lowest and $9.60 at its peak.
CRVS News
Advertisement Key Insights Corvus Pharmaceuticals' significant retail investors ownership suggests that the key decisions are influenced by shareholders from...
Corvus Pharmaceuticals (CRVS) confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical tri...